School of Pharmacy, National Defense Medical Center, Taipei, Taiwan.
Br J Clin Pharmacol. 2010 Aug;70(2):258-67. doi: 10.1111/j.1365-2125.2010.03687.x.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT * Increased frequency of electrolyte abnormalities and cardiac arrhythmias among patients exposed to digoxin-diuretic interactions has been well-documented in numerous descriptive studies. * Nonetheless, a clear causal relationship has not been established in these studies. WHAT THIS STUDY ADDS * The risks of digoxin intoxication associated with use of digoxin in combination with any diuretic use, types of diuretics, combinations of diuretics, and individual diuretics were quantified using a population-based nested case-control study design. * The combined therapy of digoxin with any diuretic is associated with a 3.08-fold increase in the risk of digoxin intoxication. * Regarding diuretic class, the risk carried by loop diuretics is greater than that of thiazides or potassium-sparing diuretics, and the risk varies with different combinations of diuretic classes and individual diuretics. AIMS To quantify the digoxin intoxication risk associated with exposure to digoxin-diuretic interactions, and evaluate whether the risk varies by diuretic type, individually or in combination. METHODS This was a population-based nested case-control study in which data from the National Health Insurance Research Database (NHIRD) in Taiwan were analysed. RESULTS The study cohort comprised 154 058 heart failure (HF) patients taking digoxin between 2001 and 2004, in whom digoxin intoxication requiring a hospitalization (ICD-9 code 972.1) occurred in 595 cases. A total of 28 243 matched controls were also selected for analysis. Cases were 3.08 times (adjusted OR 3.08, 95% CI 2.50, 3.79) more likely to have been prescribed diuretic medication in the previous month than controls. Regarding the class of diuretics, loop diuretics carried the greatest risk (adjusted OR 2.97, 95% CI 2.35, 3.75), followed by thiazides (OR 2.36, 95% CI 1.70, 3.29) and potassium-sparing diuretics (OR 1.72, 95% CI 0.83, 3.56). The risk was also observed to vary with different combinations of diuretics, and the loops/thiazides/potassium-sparing diuretics combination carried the greatest risk (adjusted OR 6.85, 95% CI 4.93, 9.53). Among the individual diuretics examined, hydrochlorothiazide carried the greatest risk (adjusted OR 4.63, 95% CI 2.50, 8.57). CONCLUSIONS This study provided empirical evidence that digoxin-diuretic interactions increased the risk of hospitalization for digoxin intoxication in HF patients. The risk was particularly high for concomitant use of digoxin with a combination of loop diuretics, thiazide and potassium-sparing diuretics. The combined use of digoxin and diuretics should be avoided if possible.
已知信息:
在众多描述性研究中,地高辛-利尿剂相互作用导致电解质异常和心律失常的频率增加,这一点已经得到充分证实。
尽管如此,这些研究并未建立明确的因果关系。
本研究新增信息:
使用基于人群的嵌套病例对照研究设计,定量评估了地高辛与任何利尿剂联合使用、利尿剂类型、利尿剂联合使用以及个体利尿剂相关的地高辛中毒风险。
地高辛与任何利尿剂联合治疗与地高辛中毒风险增加 3.08 倍相关。
就利尿剂类别而言,袢利尿剂的风险大于噻嗪类或保钾利尿剂,并且风险随不同的利尿剂类别和个体利尿剂的组合而变化。
目的:
方法:
结果:
研究队列包括 2001 年至 2004 年间服用地高辛的 154058 例心力衰竭(HF)患者,其中 595 例因地高辛中毒需要住院治疗(ICD-9 代码 972.1)。还选择了 28243 名匹配的对照进行分析。与对照组相比,病例组在前一个月更有可能被处方利尿剂(调整后的 OR 3.08,95%CI 2.50,3.79)。
就利尿剂类别而言,袢利尿剂的风险最高(调整后的 OR 2.97,95%CI 2.35,3.75),其次是噻嗪类(OR 2.36,95%CI 1.70,3.29)和保钾利尿剂(OR 1.72,95%CI 0.83,3.56)。还观察到不同的利尿剂组合也存在风险,袢利尿剂/噻嗪类/保钾利尿剂的组合风险最大(调整后的 OR 6.85,95%CI 4.93,9.53)。
在检查的个别利尿剂中,氢氯噻嗪的风险最高(调整后的 OR 4.63,95%CI 2.50,8.57)。
结论: